| Theme | Comparison of PPIs and H2RAs in the Actions and Suitable Use for the Diseases | |
|---|---|---|
| Title | Role of H2RA and PPIs in GERD Treatment | |
| Publish Date | 2005/07 | |
| Author | Susumu Kurosawa | Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical School |
| Author | Shino Ohno | Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical School |
| Author | Junichi Kawashima | Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical School |
| Author | Takashi Nakamura | Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical School |
| Author | Koji Yakabi | Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical School |
| [ Summary ] | H2RAs and PPIs are the mainstays of medical treatment for GERD. Both drugs reduce gastric acid output through different pathways. Moreover, their absorption distribution and excretion are also different. PPIs have potent acid blocking qualities, especially taken in repeated dosees. Therefore, PPIs are recommended for rather severe cases of GERD. On the other hand, H2RA possess rapid, as well as the strongest acid-blocking capacity, with the initial dose. However, the decrease of potency with repeated doses, known as tolerance, has not been determined. Therefore, H2RAs are well suited for midlevel GERD treatment. The treatment goal for endoscopy negative GERD therapy is to relieve symptoms. PPIs, as well as H2RAs, can be useful for on-demand treatment of GERD. |
|